EIF4EBP2 and glioblastoma: In contrast, EIF4EBP2 is only overexpressed in 3 out of these 17 tumor types in TCGA datasets (Fig. S7B), leading us to focus our analyses on EIF4EBP1. Indeed, we uncovered that high EIF4EBP1 expression correlated with significantly decreased overall survival in three different tumor types (Fig. 6A, Fig. S7C, D), including glioblastoma, highlighting EIF4EBP1 expression as a potential prognostic biomarker in these tumor entities.